Carbidopa

Names

[ Name ]:
Carbidopa

[Synonym ]:
Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-, hydrate (1:1)
Carbidopa
(S)-Carbidopa
1-a-(3,4-Dihydroxybenzyl)-a-hydrazinopropionic Acid
MFCD00069231
L-a-Methyldopahydrazine
(aS)-a-Hydrazino-3,4-dihydroxy-a-methylbenzenepropanoic Acid
a-Methyldopahydrazine
Lodosin
EINECS 249-271-9
carbidopa [INN_en]
(S)-(-)-Carbidopa
HMD
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid hydrate (1:1)
(2S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid
S-(−)-Carbidopa
Benzenepropanoic acid, α-hydrazinyl-3,4-dihydroxy-α-methyl-, (αS)-
benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (αS)-
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid hydrate (1:1)
benzenepropanoic acid, a-hydrazinyl-3,4-dihydroxy-a-methyl-, (aS)-
Benzenepropanoic acid, α-hydrazino-3,4-dihydroxy-α-methyl-, (S)-
S-(-)-Carbidopa
(-)-L-a-Hydrazino-3,4-dihydroxy-a-methylhydrocinnamic Acid
(2S)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid
Hydrazino-a-methyldopa

Biological Activity

[Description]:

Carbidopa is an inhibitor of DOPA decarboxylase, which is used in parkinson disease.Target: DOPA decarboxylaseCarbidopa (CD), a competitive inhibitor of aromatic l-amino acid decarboxylase that does not cross the blood-brain barrier, is routinely administered with levodopa (LD) to patients with Parkinson disease (PD) to reduce the peripheral decarboxylation of LD to dopamine [1]. CD premedication improves 11C-5-HTP PET image quality and facilitates detection of NET lesions. Because of the similarity of metabolic pathways, this method could probably be applied to improve PET imaging using other tracers like 18F-DOPA and 11C-DOPA [2]. Carbidopa (100 microM) decreased growth of (but did not kill) SK-N-SH neuroblastoma and A204 rhabdomyosarcoma cells and did not affect proliferation of DU 145 prostate, MCF7 breast, or NCI-H460 large cell lung carcinoma lines. sublethal doses of carbidopa produced additive cytotoxic effects in carcinoid cells in combination with etoposide and cytotoxic synergy in SCLC cells when coincubated with topotecan [3].

[Related Catalog]:

Signaling Pathways >> Others >> Others

Research Areas >> Neurological Disease

[References]

[1]. Durso, R., et al., Variable absorption of carbidopa affects both peripheral and central levodopa metabolism. J Clin Pharmacol, 2000. 40(8): p. 854-60.

[2]. Orlefors, H., et al., Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography. Eur J Nucl Med Mol Imaging, 2006. 33(1): p. 60-5.

[3]. Gilbert, J.A., L.M. Frederick, and M.M. Ames, The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res, 2000. 6(11): p. 4365-72.

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
528.7±50.0 °C at 760 mmHg

[ Melting Point ]:
206 - 208ºC

[ Molecular Formula ]:
C₁₀H₁₄N₂O₄

[ Molecular Weight ]:
226.23

[ Flash Point ]:
273.5±30.1 °C

[ PSA ]:
115.81000

[ LogP ]:
-0.19

[ Vapour Pressure ]:
0.0±1.5 mmHg at 25°C

[ Index of Refraction ]:
1.641

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: MW5298000

CHEMICAL NAME :: Hydrocinnamic acid, alpha-hydrazino-3,4-dihydroxy-alpha-methyl-, L-

CAS REGISTRY NUMBER :: 28860-95-9

LAST UPDATED :: 199504

DATA ITEMS CITED :: 7

MOLECULAR FORMULA :: C10-H14-N2-O4

MOLECULAR WEIGHT :: 226.26

WISWESSER LINE NOTATION :: ZMX1&VQ1R CQ DQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 2804 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 468 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 23400 mg/kg/90D-C

TOXIC EFFECTS :: Kidney, Ureter, Bladder - other changes in urine composition Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2100 mg/kg

SEX/DURATION :: female 1-21 day(s) after conception

TOXIC EFFECTS :: Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :: TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :: Oral

DOSE :: 2880 mg/kg

SEX/DURATION :: female 90 day(s) pre-mating

TOXIC EFFECTS :: Reproductive - Maternal Effects - uterus, cervix, vagina

MUTATION DATA

TYPE OF TEST :: Mutation in microorganisms

TEST SYSTEM :: Bacteria - Salmonella typhimurium

DOSE/DURATION :: 1 mg/plate

REFERENCE :: RCOCB8 Research Communications in Chemical Pathology and Pharmacology. (PJD Pub. Ltd., P.O. Box 966, Westbury, NY 11590) V.1- 1970- Volume(issue)/page/year: 49,415,1985 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4821 No. of Facilities: 17 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 303 (estimated) No. of Female Employees: 166 (estimated)

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ Hazard Codes ]:
Xi

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
3

[ RTECS ]:
MW5298000

[ HS Code ]:
2932999099

Customs

[ HS Code ]: 2932999099

[ Summary ]:
2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.

BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)

Beneficial effects of natural phenolics on levodopa methylation and oxidative neurodegeneration.

Brain Res. 1497 , 1-14, (2013)

Levodopa (L-DOPA) is widely used for symptomatic management in Parkinson's disease. We recently showed that (-)-epigallocatechin-3-gallate, a tea polyphenol, not only inhibits L-DOPA methylation, but ...

Three cases of impulse control disorder in Parkinson's disease patients receiving dopamine replacement therapy.

Ir. Med. J. 106(1) , 24-5, (2013)

Impulse control disorders (ICDs) are a known side effect of dopamine replacement therapy in patients with Parkinson's disease (PD). They can have devastating consequences for patients and their famili...